Dongwha Pharmaceutical said it has partnered with Animuscure, a Korean biotech startup, to co-develop a treatment for sarcopenia.
As part of the agreement, the two companies will conduct joint research to identify and develop innovative candidates for the new synthetic drug treatment for muscle diseases that Dongwha is investigating.
Dongwha will synthesize and derive candidate substances for the treatment of sarcopenia based on its ability to develop new drugs based on low molecular weight compounds, and Animuscure plans to conduct efficacy evaluation and mechanism research. .
Subsequently, the two companies will jointly file a patent application for the joint research result, while Dongwha will have exclusive rights to market the product.
“While we expect sarcopenia to increase with the aging of the population, there is still no adequate treatment and a high unmet medical need,” said Dongwha CEO Yoo Jun-ha. “Through this agreement, we anticipate that the research capabilities of both companies will be utilized to effectively build an innovative muscle disease treatment pipeline.”
Co-CEOs of Animuscure, Kang Jong-soon and Bae Kyu-woon, also said, “With our muscle disease R&D expertise and innovative evaluation platform, we will cooperate to achieve significant results in joint research with Dongwha.
Sarcopenia is a condition characterized by loss of skeletal muscle mass and function and is primarily a disease of the elderly. Sarcopenia is a syndrome characterized by a progressive and generalized loss of skeletal muscle mass and strength, and it is strictly correlated with physical disability, poor quality of life and death.